• VX-765 for Caspase-1 Assays

  2026-08-08

  VX-765 helps separate caspase-1-driven inflammation and pyroptosis from transcription-linked apoptosis. This workflow-focused guide covers dosing, cytokine readouts, biochemical confirmation, and troubleshooting for macrophage, lymphocyte, and translational inflammation studies.

• PYR-41: Inhibitor of Ubiquitin-Activating Enzyme E1

  2026-08-07

  PYR-41 enables upstream interrogation of ubiquitin-dependent protein turnover, NF-κB signaling, and inflammatory phenotypes in cell and animal research. Its strongest use-case is mechanistic pathway dissection, provided that solubility, exposure timing, viability, and off-target effects are controlled.

• Human iPSC Sensory Neuron Model Validates HSV-1 Latency and

  2026-08-07

  The reference study introduces a scalable system for differentiating human inducible pluripotent stem cells (hiPSCs) into functional sensory neurons, enabling robust modeling of herpes simplex virus 1 (HSV-1) latent infection and reactivation. This innovation addresses a critical gap by providing a human neuronal platform for mechanistic studies of HSV-1 latency, with implications for antiviral research and therapeutic development.

• JNK-IN-7: Unraveling Apoptotic Pathways for Translational Im

  2026-08-06

  This thought-leadership article explores how the selective JNK inhibitor JNK-IN-7 enables translational researchers to dissect apoptosis and innate immune signaling pathways, drawing on recent breakthroughs in Candida krusei-induced mammary cell apoptosis. Mechanistic insight, protocol guidance, and a forward-looking perspective are integrated to empower advanced MAPK pathway research.

• TSPAN18–STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-08-06

  Zhou et al. (2023) identify TSPAN18 as a key regulator of bone metastasis in prostate cancer by protecting STIM1 from TRIM32-mediated degradation, thus promoting calcium signaling and metastatic progression. This mechanistic insight opens new avenues for targeting bone metastasis in hormone-responsive cancers.

• SB 202190: Precision p38 MAPK Inhibition for Translational D

  2026-08-05

  SB 202190 (FHPI), a highly selective p38 MAP kinase inhibitor, is transforming translational research in inflammation, cancer, and neuroprotection. This thought-leadership article unpacks the mechanistic rationale, evidence, and strategic deployment of SB202190, building on recent MAPK/NF-κB pathway insights and offering actionable guidance for researchers seeking reproducibility and clinical relevance.

• Network Meta-Analysis: Azilsartan Medoxomil in Hypertension

  2026-08-05

  A systematic literature review and network meta-analysis compared azilsartan medoxomil (TAK 491) with other antihypertensives, finding that 80 mg azilsartan medoxomil had the highest probability of being most effective in reducing both systolic and diastolic blood pressure among mild-to-moderate hypertensive patients. These findings highlight azilsartan medoxomil’s potential for future essential hypertension treatment research and inform comparative efficacy studies.

• LY2228820: Protocols and Innovations in p38 MAP Kinase Inhib

  2026-08-04

  LY2228820 stands out as a highly selective p38 MAP kinase inhibitor for dissecting complex inflammatory and angiogenic signaling, offering robust control over phosphorylation events in experimental and translational workflows. This guide details stepwise protocols, cross-references recent anti-angiogenic innovations, and delivers actionable troubleshooting for reproducible results.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-08-04

  Explore the advanced role of 5-(N,N-dimethyl)-Amiloride hydrochloride in dissecting Na+/H+ exchanger signaling during endothelial injury and sepsis. This in-depth analysis offers a unique translational perspective, bridging molecular inhibition with vascular pathophysiology.

• Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal S

  2026-08-03

  Moxidectin, long valued for parasitic worm control, now propels antifungal innovation by enhancing polyene efficacy against Candida albicans. This article dissects experimental workflows, protocol parameters, and troubleshooting strategies for leveraging APExBIO's high-purity Moxidectin in translational research.

• TNF-alpha Recombinant Murine Protein: Optimizing Apoptosis R

  2026-08-03

  Leverage the high-specificity and bioactivity of TNF-alpha recombinant murine protein to dissect apoptosis and inflammatory pathways with unprecedented precision. This guide translates cutting-edge discoveries—including transcription-independent cell death—into actionable protocols, troubleshooting strategies, and next-gen research opportunities.

• Sulfo-NHS-Biotin: Mechanistic Precision for Translational Br

  2026-08-02

  This thought-leadership article explores the pivotal role of Sulfo-NHS-Biotin in enabling high-fidelity cell surface protein labeling for next-generation translational research. By bridging mechanistic insights with strategic application, it guides researchers on leveraging this reagent for single-cell secretion profiling, advanced affinity workflows, and the functional stratification of therapeutic cell populations. Drawing on recent SEC-seq advances and APExBIO's product leadership, the article positions Sulfo-NHS-Biotin as an essential tool for the future of precision cell therapy and proteomics.

• TPPU and sEH Inhibition: Transforming Osteoporosis Research

  2026-08-01

  This thought-leadership article explores the mechanistic advances and translational strategies enabled by TPPU, a potent soluble epoxide hydrolase inhibitor, in the context of inflammation, pain, and bone metabolism. Drawing on the latest mechanistic insights—including the regulation of osteoclastogenesis via the hepatic sEH–Nrf2 axis—this piece offers translational researchers actionable recommendations and a forward-looking perspective on how TPPU is redefining experimental design in chronic inflammation research.

• MDM1 Overexpression Enhances p53-Mediated Sensitivity in CRC

  2026-07-31

  A recent study reveals that MDM1 overexpression in colorectal cancer enhances p53 expression and apoptosis, increasing sensitivity to chemoradiotherapy. These findings identify MDM1 as a promising biomarker for predicting and improving treatment response, with implications for future translational research.

• JNK-IN-7: Advancing Translational Apoptosis and Immune Resea

  2026-07-31

  Explore how JNK-IN-7, a selective JNK inhibitor from APExBIO, empowers translational researchers to dissect apoptosis and innate immune signaling with unprecedented mechanistic clarity. By bridging recent findings on Candida krusei-induced apoptosis with advanced MAPK pathway research, this article offers actionable strategies, protocol guidance, and a forward-looking perspective for leveraging JNK-IN-7 in complex biological models.

8619 records 5/575 page Previous Next 12345 下5页 Last page